WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for JANUVIA(TM) (sitagliptin), the only DPP-4 inhibitor ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with ...

Type II diabetes costs the NHS £8.8 billion a year. Novo Nordisk has announced that its oral semaglutide improved glycaemic control in people with type II diabetes across baseline HbA1c levels in the ...

Unichem has obtained tentative approval from the Food and Drug Administration for sitagliptin tablets in dosage strengths of 25 mg, 50 mg, and 100 mg The medication is a generic of Merck Sharpe and ...

MUNICH -- For type 2 diabetes patients uncontrolled on metformin and sitagliptin (Januvia), adding the novel sodium/glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin improved glycemic levels, a ...

Januvia (sitagliptin) is a prescription drug that’s used to treat type 2 diabetes. This drug can interact with other medications. For example, Januvia can interact with other diabetes medications and ...

Adjunct to diet and exercise in type 2 diabetes, as monotherapy or in combination with either metformin or a thiazolidinedione. Incretins, such as glucagonlike peptide-1 (GLP-1) and glucose-dependent ...

COPENHAGEN, June 26 (Reuters) - Novo Nordisk said on Saturday extension data from a study showed its new diabetes drug Victoza provided better blood sugar control and also weight reduction than ...

EpiPen, Invokana, Tecfidera, Advair Diskus, and Januvia are top-selling medicines that cost less to buy in Canada than in the United States. A lot of the discussion related to curbing runaway drug ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with ...